The global sales of Genito Urinary System and Sex Hormones show significant variation by country. In 2023, Japan led with sales valued at 1.62 billion US dollars PPP, followed by Canada at 1.27 billion. Croatia showed a strong growth trend with a 2.95% increase, whereas Finland experienced a notable decline of 6.13%. Noteworthy positive growth was also seen in Ireland at 5.75% and Switzerland at 1.85%. Despite Greece's substantial decline of 2.67%, countries like Latvia and Estonia managed small positive growth.
The future of Genito Urinary System and Sex Hormones sales points to expanding markets in countries with growing aging populations and increased healthcare access, potentially driving innovation in product offerings and market penetration strategies.
Top countries in Genito Urinary System and Sex Hormones Sales by Country
| # | 10 Countries | Million US Dollars PPP | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Japan | 1,620 | 2023 | +1.42% | +1.36% | View data |
| 2 | 2 Canada | 1,270 | 2023 | +1.52% | -0.43% | View data |
| 3 | 3 Croatia | 489.5 | 2023 | +2.81% | +2.95% | View data |
| 4 | 4 Switzerland | 317.1 | 2023 | +2.13% | +1.85% | View data |
| 5 | 5 Belgium | 307.5 | 2023 | -2.07% | +1.59% | View data |
| 6 | 6 Greece | 258.7 | 2023 | +2.29% | -2.67% | View data |
| 7 | 7 Ireland | 122.2 | 2023 | +1.83% | +5.75% | View data |
| 8 | 8 Finland | 94.4 | 2023 | -7.81% | -6.13% | View data |
| 9 | 9 Slovenia | 37.2 | 2023 | +4.2% | -1.34% | View data |
| 10 | 10 Latvia | 30.5 | 2023 | -4.69% | +0.26% | View data |
